Trial Profile
Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Inecalcitol (Primary) ; Imatinib
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms INIM study
- Sponsors ATON
- 07 Jul 2018 Status changed from recruiting to discontinued.
- 12 May 2017 According to a Hybrigenics media release, the company presented encouraging initial results for inecalcitol in combination with oral imatinib in chronic myeloid leukaemia.
- 22 Apr 2015 New trial record